Arthneeti

Syschem (India) Share Price & Earnings Call Analysis

₹34.03+3.31% today
Market cap
₹182 Cr
P/E
29.67
ROE
10.23%
PEG
0.86
Price to sales
0.31
Debt to equity
0.01
52W high / low
₹59.7 / ₹29.4
Sales growth (5Y)
52.98%
EBITDA margin
3.48%
Net profit margin
1.90%
Promoter holding
63.38%
Sales (last year)
₹583 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Syschem (India) rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Syschem (India).

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Syschem (India)

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Syschem (India)

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +48.9143.1037.1143.7474.7187.5347.5277.76118.87109.32103.60141.50219.35
Expenses +46.3940.6535.2642.6673.0986.7247.4576.56116.97106.86100.30135.54209.98
Operating Profit2.522.451.851.081.620.810.071.201.902.463.305.969.37
OPM %5.15%5.68%4.99%2.47%2.17%0.93%0.15%1.54%1.60%2.25%3.19%4.21%4.27%
Other Income +0.060.000.000.010.150.010.000.020.020.010.010.000.00
Interest-0.040.100.030.110.010.000.030.040.000.040.010.172.04
Depreciation0.590.680.700.740.670.680.680.680.910.760.760.821.73
Profit before tax2.031.671.120.241.090.14-0.640.501.011.672.544.975.60
Tax %80.79%0.00%0.00%0.00%123.85%0.00%0.00%0.00%54.46%0.00%25.59%15.90%68.93%
Net Profit +0.391.681.120.23-0.260.14-0.640.500.461.671.904.171.74
EPS in Rs0.100.420.280.06-0.070.04-0.160.130.110.380.440.960.36

Financials of Syschem (India)

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +114136793776859114199332574
Expenses +145126389777358105192328553
Operating Profit-3-1034-0-5197421
OPM %-23%-24%0%5%4%-0%-7%1%8%4%1%4%
Other Income +00-0-0-00-000000
Interest100000000002
Depreciation222222233334
Profit before tax-5-3-212-2-7-264115
Tax %-26%-27%-30%43%50%-16%-24%-22%27%33%54%26%
Net Profit +-4-2-101-2-6-253011
EPS in Rs-1.94-1.13-0.750.170.32-0.79-2.07-0.591.130.690.112.23
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Syschem (India)

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161616161919222332404449
Reserves-6-8-10-8-8-10-15-16-10174873
Borrowings +2827222016171622000
Other Liabilities +131216293536555169107126169
Total Liabilities514744586262776093164217292
Fixed Assets +343230292728303231315368
CWIP111001100400
Investments000000000000
Other Assets +161514283534462862129164224
Total Assets514744586262776093164217292

Financials of Syschem (India)

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1060-2341-8-26-108
Cash from Investing Activity +00002-4-4-1-2-6-22-20
Cash from Financing Activity +-2-1-7-0-0-0-0-011323418
Net Cash Flow-10-000-0-001-026
Free Cash Flow106-1-20-1-2-10-32-32-11
CFO/OP-56%-53%12,760%9%-24%-3,456%-40%107%-79%-348%-238%54%

Financials of Syschem (India)

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days18727212447214731211351269992
Inventory Days22886818280104110199152611078141
Days Payable290870424151131175221186158198143112
Cash Conversion Cycle124271-119-24-7-199-1438343621
Working Capital Days-139-564-319-50-20-36-1-1548543929
ROCE %-11%-8%-6%3%7%-8%-29%-12%38%11%1%16%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Aarti Drugs (Q2 FY27)

    826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals